Transforming the Patient Journey Post-COVID

The challenges healthcare executives and administrators face are constantly changing. Host Kevin Stevenson talks with the heroes behind the heroes that are enabling hospitals, urgent care centers and telemedicine operators to spend their time tending to patients, while they handle the logistics.

 

The digital consumer experience applies to much more than retail. It’s also integral for healthcare patients. As healthcare accelerated its digital channels in the pandemic, what does this mean for the consumer experience? To answer those questions, Astound Commerce, a global digital commerce platform, created the report, Transforming the Global Healthcare Consumer Journey: Now and Beyond Covid-19Talking about what they learned from this is Tina Wilson, VP of Global Health and Life Sciences.

The survey included 1,000 healthcare consumers all over the world. It asked them about their patient experiences. It looked at access to healthcare and the reception of telehealth. The insights were powerful. Tina said, “What surprised me the most was the significant challenge for women’s health. Only 21% of women felt very confident that they could afford an emergency healthcare situation.”

Along with the inequality of women, the study showed many disparities, supporting the importance of social determinants of health (SDOH) impact on access. “Only 40% of all respondents said they had adequate access to care,” Wilson added.

Different regions of the world also had different perspectives. “Those in South America were very responsive and had positive responses to healthcare. The EU less because of uncertainty around Brexit,” Wilson explained.

So how can providers better engage with patients to ensure better experiences and outcomes? Tina commented, “Patients are consumers. It’s relatively the same experience journey with other brands. And patients are adopting digital channels.”

The study revealed that 41% of respondents had used telehealth, and appointment scheduling online was up 39%. These data points further substantiate the consumerism of healthcare.

Wilson also spoke about the trends emerging in 2021, and it comes down to one word—data. “We’ll see trends toward accurate data, and companies need to process and act on it fast,” she noted.

Listen to Previous Episodes of MarketScale’s I Don’t Care Right Here!

Follow us on social media for the latest updates in B2B!

Image

Latest

cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More
organoids
Growing the Future of Cancer Research: Inside the Promise of Organoids
April 19, 2025

In an era where precision and predictability define the future of oncology, organoid technology is emerging as a transformative tool in drug discovery. These miniature, lab-grown 3D tissues mirror real human biology more closely than traditional 2D models or even animal systems, offering researchers the potential to predict patient-specific drug responses. As organoids become more…

Read More